10x Genomics stock
Price history
+255.90% over the period1 year: from $16.35 (November 13, 2025) to $58.19 (November 13, 2026), +255.90%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $58.19 |
| October 30, 2026 | $70.11 |
| September 30, 2026 | $90.36 |
| August 31, 2026 | $62.45 |
| July 31, 2026 | $47.27 |
| June 30, 2026 | $38.34 |
| May 29, 2026 | $28.31 |
| April 30, 2026 | $22.05 |
| March 31, 2026 | $21.23 |
| February 27, 2026 | $23.05 |
| January 30, 2026 | $20.20 |
| December 31, 2025 | $16.31 |
| November 28, 2025 | $18.81 |
| November 13, 2025 | $16.35 |
At a glance
The company
Develops instruments, consumables, and software for single-cell and spatial analysis of biological systems
Latest results
Quarter to September 30, 2026 · EPS $0.03 (estimate -$0.26)
TickerLandia's take on 10x Genomics
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−43.40% from the 52-week high
Analysts · 17 analysts
Average target$68.14+17.10% vs. price
Buy 6 · Hold 11 · Sell 0 · Buy
TickerLandia Fingerprint: 10x Genomics
Compared with similar companies: very low earnings stability, very high price, and very high financial strength.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high89
How much it costs relative to what it produces.
Metric Value Position in group Price/book 9.13 85 Price/sales 12.4 92 Profitabilityvery low18
How much it earns on revenue and capital.
Metric Value Position in group Operating margin −10.6% 2 Gross margin 72.0% 85 Net margin −10.8% 2 ROE −8.3% 2 ROA −3.9% 2 Earnings stabilityvery low2
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 10.4% 2 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 2 Growthlow24
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −150.16% 2 Average revenue growth (3 years) +7.57% 60 Revenue growth (year over year) +1.10% 11 Financial strengthvery high89
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.09 82 Current ratio 5.12 95 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong88
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +3.21% 56 Relative strength (6 months) +171.89% 100 1-year return +255.90% 100 Distance from 200-day average +36.66% 98 Riskvery high87
How much the price swings.
Metric Value Position in group Beta (1 year) 2.49 90 Volatility (60 days) 91.1% 97 Maximum drawdown (12 months) 40.6% 74
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
10x Genomics is pricier than similar companies
10x Genomics's Price/book: 9.13, +82% against the median of a group of 11 similar companies (5.03).
Compared with 11 similar companies
| Metric | 10x Genomics | Position in the group | Band |
|---|---|---|---|
| Operating margin | -10.6% | Low | |
| ROE | -8.3% | Low | |
| Debt/equity | 0.09 | Low | |
| Price/book | 9.13 | High | |
| Net margin | -10.8% | Low |
Grey band: the middle half of the group; tick: the median; dot: 10x Genomics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$151.04M
Latest quarter · Q2 2026
Net income
-$17.93M
Latest quarter · Q2 2026
Quarterly net margin
-11.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $7.65B
- EPS
- -$0.52
- Volume
- 2.12M
- Daily trading
- €194.92M
- Dividend yield
- 0.00%
How 10x Genomics is changing
All resultsRevenue grew 16.6% a year on average over the last 5 years
Operating margin rose from −31.7% to −15.6%
Shares outstanding up 23.3% in 5 years
Returns
10x Genomics returns
$1,000 invested in 10x Genomics 5 years ago, on November 15, 2021, would be worth $368 today: −63.17% in total, −18.13% per year. This is the price return only: dividends are excluded.
| Period | 10x Genomics | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −18.94% | −3.12% | $811 |
| 6 months | +176.17% | +1.58% | $2,762 |
| Year to date | +256.77% | +10.46% | $3,568 |
| 1 year | +255.90% | +12.23% | $3,559 |
| 3 years | +60.21% | +71.41% | $1,602 |
| 5 years | −63.17% | +61.48% | $368 |
Over the last 6 months it has done better than 100% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
10x Genomics: technical analysis
10x Genomics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 71.2% below its all-time closing high ($202.37, April 26, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 39
- Between 30 and 70
- vs 200-session average
- +36.66%
Support and resistance
Price areas where 10x Genomics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$67.10+15.30%2 touches, last on October 22, 2026
- Resistance$59.70+2.59%2 touches, last on August 31, 2026
- Last price$58.19
- Support$43.16−25.83%2 touches, last on August 7, 2026
- Support$35.38−39.19%2 touches, last on July 8, 2026
- Support$24.11−58.56%4 touches, last on May 6, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.49
- Volatility (60 sessions, annualised)
- 91.1%
- Largest fall in the last year
- −40.60%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
10x Genomics: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for 10x Genomics has been November: +17.31% on average, positive in 5 years out of 7. The weakest has been March: −7.87% on average, positive in 2 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.23% | +19.86% | 5 of 7 |
| February | −3.63% | +1.47% | 4 of 7 |
| March | −7.87% | −7.90% | 2 of 7 |
| April | −4.17% | −5.27% | 3 of 7 |
| May | +2.29% | +0.06% | 4 of 7 |
| June | +8.84% | +8.79% | 5 of 7 |
| July | +7.28% | +10.14% | 5 of 7 |
| August | +3.75% | +4.16% | 4 of 7 |
| September | −2.54% | −13.67% | 2 of 7 |
| October | −2.26% | +2.62% | 4 of 8 |
| November | +17.31% | +11.88% | 5 of 7 |
| December | +1.05% | −5.74% | 2 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
10x Genomics and its competitors
Based in Pleasanton, California, and in existence since 2012, 10x Genomics supplies researchers with tools for studying biological samples at the level of individual cells and tissue locations. Its Chromium system covers single-cell analysis through microfluidic chips, reagents and kits, while the Visium platform maps gene expression across tissue slides and the Xenium Analyzer detects RNA targets in situ. Customers include academic and government institutions, biopharmaceutical companies and biotechnology firms, served across the United States, Europe, the Middle East, Africa, China and the rest of Asia Pacific.
- Headquarters
- Pleasanton, United States
- Employees
- 1,178
- Founded
- 2012
- Chief executive
- Serge Saxonov
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| 10x GenomicsTXG | $7.65B | -10.6% | — | +176.17% |
| InsuletPODD | $10.58B | 18.4% | 24.9 | +2.45% |
| PenumbraPEN | $12.65B | 12.1% | 80.8 | −0.52% |
| Zimmer Biomet HoldingsZBH | $19.53B | 16.7% | 26.1 | +24.77% |
| SterisSTE | $25.67B | 19.2% | 31.4 | +25.21% |
| DexComDXCM | $31.08B | 24.0% | 32.8 | +42.27% |
Same industry or related industries, similar size. Compare 10x Genomics with its competitors · Full profile
